CN114099500A - 依达拉奉缓释药物组合物、制备方法及应用 - Google Patents
依达拉奉缓释药物组合物、制备方法及应用 Download PDFInfo
- Publication number
- CN114099500A CN114099500A CN202110999891.6A CN202110999891A CN114099500A CN 114099500 A CN114099500 A CN 114099500A CN 202110999891 A CN202110999891 A CN 202110999891A CN 114099500 A CN114099500 A CN 114099500A
- Authority
- CN
- China
- Prior art keywords
- edaravone
- active ingredient
- pharmaceutical composition
- pharmaceutical
- hypromellose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 title claims abstract description 96
- 229950009041 edaravone Drugs 0.000 title claims abstract description 96
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 53
- 238000013268 sustained release Methods 0.000 title claims abstract description 20
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 69
- 239000000463 material Substances 0.000 claims abstract description 42
- 239000003814 drug Substances 0.000 claims abstract description 24
- 239000000945 filler Substances 0.000 claims abstract description 15
- 239000000314 lubricant Substances 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 229920000642 polymer Polymers 0.000 claims abstract description 9
- 239000010410 layer Substances 0.000 claims abstract description 6
- 239000011230 binding agent Substances 0.000 claims abstract description 5
- 239000011247 coating layer Substances 0.000 claims abstract description 5
- 239000007884 disintegrant Substances 0.000 claims abstract description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 48
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 31
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 31
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- 235000019359 magnesium stearate Nutrition 0.000 claims description 24
- 239000007962 solid dispersion Substances 0.000 claims description 21
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 20
- 229960003943 hypromellose Drugs 0.000 claims description 19
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 18
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 18
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 18
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 15
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 15
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 13
- 239000008101 lactose Substances 0.000 claims description 13
- 229920000881 Modified starch Polymers 0.000 claims description 12
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 229960000913 crospovidone Drugs 0.000 claims description 11
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 11
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 11
- 239000007939 sustained release tablet Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- -1 carboxymethyl ethyl Chemical group 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 7
- 239000007888 film coating Substances 0.000 claims description 7
- 238000009501 film coating Methods 0.000 claims description 7
- 230000036542 oxidative stress Effects 0.000 claims description 7
- 229940069328 povidone Drugs 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 6
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 6
- 230000001070 adhesive effect Effects 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 206010008118 cerebral infarction Diseases 0.000 claims description 6
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 239000001856 Ethyl cellulose Substances 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 235000021355 Stearic acid Nutrition 0.000 claims description 5
- 229920001531 copovidone Polymers 0.000 claims description 5
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 5
- 229920001249 ethyl cellulose Polymers 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 5
- 239000011118 polyvinyl acetate Substances 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- 239000008117 stearic acid Substances 0.000 claims description 5
- 238000005550 wet granulation Methods 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 238000007907 direct compression Methods 0.000 claims description 4
- 238000007908 dry granulation Methods 0.000 claims description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
- 239000012188 paraffin wax Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 3
- 206010039966 Senile dementia Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 3
- 239000008116 calcium stearate Substances 0.000 claims description 3
- 235000013539 calcium stearate Nutrition 0.000 claims description 3
- 229960005168 croscarmellose Drugs 0.000 claims description 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 3
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 210000000987 immune system Anatomy 0.000 claims description 3
- 208000026278 immune system disease Diseases 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 claims description 3
- 229960000502 poloxamer Drugs 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 201000005060 thrombophlebitis Diseases 0.000 claims description 3
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 239000004925 Acrylic resin Substances 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 235000013871 bee wax Nutrition 0.000 claims description 2
- 229940092738 beeswax Drugs 0.000 claims description 2
- 239000012166 beeswax Substances 0.000 claims description 2
- 239000007767 bonding agent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 239000004203 carnauba wax Substances 0.000 claims description 2
- 235000013869 carnauba wax Nutrition 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 229960000541 cetyl alcohol Drugs 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 229940049654 glyceryl behenate Drugs 0.000 claims description 2
- 229940074045 glyceryl distearate Drugs 0.000 claims description 2
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000004200 microcrystalline wax Substances 0.000 claims description 2
- 235000019808 microcrystalline wax Nutrition 0.000 claims description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- OKODKVMXHLUQSW-JITBQSAISA-M sodium;(e)-4-hydroxy-4-oxobut-2-enoate;octadecanoic acid Chemical compound [Na+].OC(=O)\C=C\C([O-])=O.CCCCCCCCCCCCCCCCCC(O)=O OKODKVMXHLUQSW-JITBQSAISA-M 0.000 claims description 2
- 229940012831 stearyl alcohol Drugs 0.000 claims description 2
- 229940045860 white wax Drugs 0.000 claims description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 102000004420 Creatine Kinase Human genes 0.000 description 4
- 108010042126 Creatine kinase Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OTCCIMWXFLJLIA-UHFFFAOYSA-N N-acetyl-DL-aspartic acid Natural products CC(=O)NC(C(O)=O)CC(O)=O OTCCIMWXFLJLIA-UHFFFAOYSA-N 0.000 description 3
- OTCCIMWXFLJLIA-BYPYZUCNSA-N N-acetyl-L-aspartic acid Chemical compound CC(=O)N[C@H](C(O)=O)CC(O)=O OTCCIMWXFLJLIA-BYPYZUCNSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010053425 Injection site swelling Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009477 fluid bed granulation Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000009478 high shear granulation Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
Abstract
本发明公开了一种依达拉奉缓释药物组合物、制备方法及应用。本发明公开了一种药物组合物,其包括以下组分:药物层和包衣层;药物层包括依达拉奉药物活性成分、聚合物载体、骨架缓释材料和其他辅料;其他辅料包括填充剂、粘合剂、崩解剂和润滑剂中的一种或多种。本发明的药物组合物,可每日服药1次,在24小时内缓慢释放药物,使其可长期在体内维持平稳有效的血药浓度,减少给药次数,改善患者顺应性,市场化前景好。
Description
本申请要求享有2020年8月26日向中国国家知识产权局提交的申请号为202010871330.3,名称为“依达拉奉缓释药物组合物、制备方法及应用”的发明专利申请的优先权。该申请的全文以引用的方式并入本文。
技术领域
本发明涉及一种依达拉奉缓释药物组合物、制备方法及应用。
背景技术
依达拉奉是一种脑保护剂(自由基清除剂)。临床研究提示N-乙酰门冬氨酸(NAA)是特异性的存活神经细胞的标志,脑梗塞发病初期含量急剧减少。脑梗塞急性期患者给予依达拉奉,可抑制梗塞周围局部脑血流量的减少,使发病后第28天脑中NAA含量较甘油对照组明显升高,因此依达拉奉用于改善急性脑梗塞所致的神经症状、日常生活活动能力和功能障碍。
上市依达拉奉制剂为注射液,通常成人依达拉奉30mg,一日2次,用时以适量的生理盐水稀释,30分钟内静脉滴注完。发病后24小时内开始给药,疗程为14天。一天2次静脉滴注患者的顺应性较差,且毒副作用包括急性肾功能衰竭、肝功能障碍、黄疸、血小板减少、弥散性血管内凝血(DIC),注射部位发疹、红肿,疱疹,瘙痒感,嗳气,发热,热感,血压上升,血清胆固醇升高,血清胆固醇降低,三酰甘油升高,血清总蛋白减少,肌酸激酶(CK)、肌酸磷酸激酶(CPK)降低,血清钙低下。
依达拉奉在甲醇、乙醇中溶解,在水中溶解度小于1mg/mL。依达拉奉的pKa为7.0,水中的溶解度具有pH依赖性,从pH2-pH7基本不变,从pH 8到pH 10溶解度逐渐增加。
因此有必要开发一种依达拉奉口服缓释制剂,提高其生物利用度、释药速度平稳,可显著提高患者用药顺应性及降低毒副作用。
发明内容
为改善上述技术问题,本发明提供一种药物组合物,其中所述药物组合物具有以下特征A)、B)和C):
A)在1小时内溶出不超过35%的药物活性成分;
B)在6小时内溶出30%~65%的药物活性成分;
C)在24小时内溶出不低于75%的药物活性成分;
其中,所述的药物活性成分可以选自依达拉奉、其药学上可接受的盐、水合物和溶剂合物中的一种或多种。
根据本发明的实施方案,所述药物组合物优选具有以下特征A)、B)和C):
A)在1小时内溶出不超过30%的药物活性成分;
B)在6小时内溶出30%~60%的药物活性成分;
C)在24小时内溶出不低于75%的药物活性成分;
根据本发明的实施方案,所述药物组合物更优选具有以下特征A)、B)和C):
A)在1小时内溶出不超过25%的药物活性成分;
B)在6小时内溶出35%~60%的药物活性成分;
C)在24小时内溶出不低于80%的药物活性成分。
其中,所述“溶出”指药物活性成分(如依达拉奉)的累积溶出度;进一步地,所述累积溶出度在pH 6.8磷酸盐缓冲液中测得。本领域技术人员能够理解,随着时间增加,所述药物活性成分(如依达拉奉)的溶出度逐渐增加。
根据本发明的实施方案,所述药物组合物为缓释组合物,优选为24小时内持续缓释的药物组合物。
本发明还提供一种药物组合物,其包括以下组分:药物层和包衣层;所述的药物层包括依达拉奉药物活性成分、聚合物载体、骨架缓释材料和其他辅料;所述的其他辅料包括填充剂、粘合剂、崩解剂和润滑剂中的一种或多种。
根据本发明的实施方案,所述的包衣层优选为薄膜包衣。
根据本发明的实施方案,所述的依达拉奉药物活性成分可以选自依达拉奉、其药学上可接受的盐、水合物和溶剂合物中的一种或多种。
根据本发明的实施方案,所述的依达拉奉溶剂合物中的溶剂可以为有机溶剂,所述有机溶剂可以为本领域已知的有机溶剂,例如甲醇、乙醇、四氢呋喃和乙醚等中的一种或多种。
根据本发明的实施方案,所述的依达拉奉药物活性成分的含量优选5.0%~65.0%,例如5.0%、6.0%、7.0%、8.0%、9.0%、10.0%、11.0%、12.0%、13.0%、14.0%、15.0%、20.0%、25.0%、30.0%、35.0%、40.0%、45.0%、50.0%、55.0%、60.0%或65.0%;其中,所述的含量是指以依达拉奉计,依达拉奉药物活性成分的重量占药物组合物总重量的百分比。
根据本发明的实施方案,所述的聚合物载体选自聚乙二醇、共聚维酮(PVP/VA)、羟丙甲纤维素(如K4M或K100Lv)、醋酸羟丙甲纤维素琥珀酸酯(HPMCAS)、羟丙甲纤维素邻苯二甲酸酯(HPMCP)、聚醋酸乙烯酯聚维酮混合物、泊洛沙姆和羧甲基乙基纤维素(CMEC)中的一种或多种。
根据本发明的实施方案,所述的聚合物载体的含量优选10.0%~80.0%,所述的含量是指聚合物载体的重量占药物组合物总重量的百分比。
根据本发明的实施方案,所述的骨架缓释材料优选羟丙基甲基纤维素、羟丙基纤维素、海藻酸钠、羧甲基纤维素、羧甲基纤维素钠、甲基纤维素、聚丙烯酸树脂、乙基纤维素、卡波姆、硬脂酸、聚氧乙烯、聚醋酸乙烯酯聚维酮混合物、单硬脂酸甘油酯、双硬脂酸甘油酯、山嵛酸甘油酯、十六醇、十八醇、蜂蜡、氢化蓖麻油、巴西棕榈蜡、石蜡、白蜡和微晶蜡中的一种或多种。
根据本发明的实施方案,所述的骨架缓释材料的含量优选5.0%~50.0%,例如5.0%、10.0%、15.0%、20.0%、25.0%、30.0%、35.0%、40.0%、45.0%或50.0%;其中,所述的含量是指骨架缓释材料的重量占药物组合物总重量的百分比。
根据本发明的实施方案,所述的填充剂可以为本领域已知的填充剂,优选微晶纤维素、预胶化淀粉、淀粉、乳糖、甘露醇、磷酸氢钙和硅化微晶纤维素中的一种或多种;例如可以为淀粉、乳糖和甘露醇中的一种或多种。
当骨架缓释材料采用亲水凝胶骨架材料时,优选水溶性辅料作为填充剂,所述的水溶性辅料例如乳糖、甘露醇和淀粉等,其优点在于难溶性药物释放时,水溶性辅料溶解(例如乳糖、甘露醇和淀粉等),提高孔隙率,充当致孔剂,与骨架缓释材料共同控制释放性能。
根据本发明的实施方案,所述的填充剂的含量优选10.0%~60.0%,例如10.0%、11.0%、12.0%、13.0%、14.0%、15.0%、20.0%、25.0%、30.0%、35.0%、40.0%、45.0%、50.0%、55.0%或60.0%;其中,所述的含量是指填充剂的重量占药物组合物总重量的百分比。
根据本发明的实施方案,所述的粘合剂可以为本领域已知的具有粘性的物质,优选聚维酮(又名聚乙烯吡咯烷酮,PVP)、甲基纤维素、羟丙基甲基纤维素、羟乙基纤维素、共聚维酮、羧甲基纤维素钠、羟丙基纤维素和海藻酸钠中的一种或多种。
根据本发明的实施方案,所述的粘合剂的含量优选5.0%~30.0%,例如5.0%、6.0%、7.0%、8.0%、9.0%、10.0%、11.0%、12.0%、13.0%、14.0%、15.0%、20.0%、25.0%或30.0%;其中,所述的含量是指粘合剂的重量占药物组合物总重量的百分比。
根据本发明的实施方案,所述的崩解剂可以为本领域中常规的具有崩解作用的物质,优选交联聚维酮、交联羧甲基纤维素钠、交联羧甲基纤维素钙、羧甲基淀粉钠,羟丙纤维素和预胶化淀粉中的一种或多种,进一步优选交联聚维酮、交联羧甲基纤维素钠和交联羧甲基纤维素钙中的一种或多种。
根据本发明的实施方案,所述的润滑剂可以为具有润滑作用的物质,优选硬脂酸钙、硬脂酸镁、硬脂酸锌、硬脂酸、硬脂酸富马酸钠、聚乙二醇、淀粉、滑石粉和石蜡中的一种或多种,进一步优选硬脂酸镁、硬脂酸钙和硬脂酸中的一种或多种。
根据本发明的实施方案,所述的润滑剂的含量优选0%~5%,例如0.1%、0.5%、1.0%、2.0%、3.0%、4.0%或5.0%;其中,所述的含量是指润滑剂的重量占药物组合物总重量的百分比。
根据本发明的实施方案,所述的其他辅料的含量优选30.0%~80.0%,例如30.0%、35.0%、40.0%、45.0%、50.0%、55.0%、6.0%、65.0%、70.0%、75.0%或80.0%;其中,所述的含量是指其他辅料的重量占药物组合物总重量的百分比。
根据本发明的实施方案,所述的药物组合物优选具有以下重量百分比的任一组分:
组分一:10.0%-30.0%依达拉奉药物活性成分,10.0%-30.0%醋酸羟丙甲纤维素琥珀酸酯,10.0%-30.0%羟丙甲纤维素K4M,5.0%-20.0%羟丙甲纤维素K100Lv,10.0%-30.0%乳糖,5.0%-20.0%微晶纤维素和0.5%-2.0%硬脂酸镁;
组份二:10.0%-30.0%依达拉奉药物活性成分,10.0%-30.0%醋酸羟丙甲纤维素琥珀酸酯,10.0%-30.0%羟丙甲纤维素K100Lv,10.0%-30.0%预胶化淀粉,5.0%-20.0%交联聚维酮,5.0%-20.0%微晶纤维素和0.5%-2.0%硬脂酸镁;
组分三:10.0%-30.0%依达拉奉药物活性成分、40.0%-60.0%醋酸羟丙甲纤维素琥珀酸酯,5.0%-20.0%羟丙甲纤维素K4M,5.0%-20.0%羟丙甲纤维素K100Lv,5.0%-20.0%乳糖,5.0%-20.0%微晶纤维素和0.5%-2.0%硬脂酸镁;
组分四:10.0%-30.0%依达拉奉药物活性成分,40.0%-60.0%醋酸羟丙甲纤维素琥珀酸酯,5.0%-20.0%羟丙甲纤维素K100Lv,5.0%-20.0%预胶化淀粉,5.0%-20.0%交联聚维酮,5.0%-20.0%微晶纤维素和0.5%-2.0%硬脂酸镁;
根据本发明的实施方案,所述的药物组合物也可以为具有以下重量百分比的任一组分:
组分一:20.00%依达拉奉药物活性成分,20.00%醋酸羟丙甲纤维素琥珀酸酯,20.00%羟丙甲纤维素K4M,10.00%羟丙甲纤维素K100Lv,19.00%乳糖,10.00%微晶纤维素和1.00%硬脂酸镁;
组份二:20.00%依达拉奉药物活性成分,20.00%醋酸羟丙甲纤维素琥珀酸酯,19.00%羟丙甲纤维素K100Lv,20.00%预胶化淀粉,10.00%交联聚维酮,10.00%微晶纤维素和1.00%硬脂酸镁;
组分三:16.67%依达拉奉药物活性成分、50.00%醋酸羟丙甲纤维素琥珀酸酯,8.33%羟丙甲纤维素K4M,8.33%羟丙甲纤维素K100Lv,8.33%乳糖,7.34%微晶纤维素和1.00%硬脂酸镁;
组分四:16.67%依达拉奉药物活性成分,50%醋酸羟丙甲纤维素琥珀酸酯,8.33%羟丙甲纤维素K100Lv,8.33%预胶化淀粉,7.34%交联聚维酮,8.33%微晶纤维素和1.00%硬脂酸镁。
除非另有说明,本发明上下文中依达拉奉药物活性成分的含量或比例以依达拉奉计。
本发明还提供一种依达拉奉药物活性成分分散体,包括分散于聚合物载体中的依达拉奉药物活性成分。优选地,所述的聚合物载体选自聚乙二醇、共聚维酮、羟丙甲纤维素、醋酸羟丙甲纤维素琥珀酸酯、羟丙甲纤维素邻苯二甲酸酯、聚醋酸乙烯酯聚维酮混合物、泊洛沙姆和羧甲基乙基纤维素中的一种或多种。
根据本发明的实施方案,在所述依达拉奉药物活性成分分散体中,依达拉奉药物活性成分与聚合物载体的质量比可以为1:1或更低,例如1:2、1:3、1:4、1:5、1:6或更低。
本发明还提供一种药物组合物,其中所述药物组合物包含所述依达拉奉药物活性成分分散体。
根据本发明的实施方案,所述的药物组合物可以为缓释制剂,优选缓释固体制剂,例如选自缓释片、缓释胶囊和缓释微丸等剂型中的一种。
本发明还提供了所述药物组合物的制备方法,其可以选自湿法制粒法(例如流化床制粒法或高剪切制粒),干法制粒法或直接压片法等。
根据本发明的实施方案,湿法制粒优选包括以下步骤:将依达拉奉药物活性成分和醋酸羟丙甲纤维素琥珀酸酯溶解于甲醇/水溶液中,经喷雾干燥得依达拉奉药物活性成分固体分散体;将依达拉奉药物活性成分固体分散体与骨架缓释材料及部分其他辅料(包括粘合剂、填充剂和崩解剂中的一种或多种)混合,湿法制粒,干燥,整粒,然后再与润滑剂混合,压片,包衣(薄膜包衣),即得到依达拉奉药物活性成分缓释片。
根据本发明的实施方案,干法制粒优选包括以下步骤:将依达拉奉药物活性成分和醋酸羟丙甲纤维素琥珀酸酯溶解于甲醇/水溶液中,经喷雾干燥得依达拉奉药物活性成分固体分散体;将依达拉奉药物活性成分固体分散体与骨架缓释材料及部分其他辅料(包括粘合剂、填充剂、崩解剂和润滑剂中的一种或多种),干法制粒,然后再与外加润滑剂混合,压片,包衣(薄膜包衣)即得到依达拉奉药物活性成分缓释片。
根据本发明的实施方案,直接压片法优选包括以下步骤:将依达拉奉药物活性成分和醋酸羟丙甲纤维素琥珀酸酯溶解于甲醇/水溶液中,经喷雾干燥得依达拉奉药物活性成分固体分散体;将依达拉奉药物活性成分固体分散体与骨架缓释材料和其他辅料混合,压片,包衣(薄膜包衣)得到依达拉奉药物活性成分缓释片。
本发明还提供所述的药物组合物在制备治疗和/或预防氧化性应激相关疾病的药物中的应用。
本发明还提供一种治疗和/或预防氧化性应激相关疾病的方法,包括将所述药物组合物给予有需要的患者(例如人)。
根据本发明的实施方案,所述的氧化性应激相关疾病选自老年痴呆症(阿尔茨海默症)、ALS(肌萎缩侧索硬化症)、帕金森氏病、缺血性心脏病、脑梗/中风、血栓性静脉炎、COPD(慢性阻塞性肺疾病)、HIV/AIDS(人类免疫系统病/获得性免疫系统综合症)和糖尿病。
本发明的积极进步效果在于:本发明的药物组合物,可每日服药1次,在24小时内缓慢释放药物,使其可长期在体内维持平稳有效的血药浓度,减少给药次数,改善患者顺应性,市场化前景好。
具体实施方式
下面通过实施例的方式进一步说明本发明,但并不因此将本发明限制在所述的实施例范围之中。下列实施例中未注明具体条件的实验方法,按照常规方法和条件,或按照商品说明书选择。
除非另有说明,下文实施例所使用的原料和试剂是可商购的或可由本领域技术人员通过已知的方法制备。
实施例1-2
依达拉奉缓释片处方组成
制备工艺:
步骤1:将上述处方中的依达拉奉和HPMCAS加入到溶剂中(甲醇:水=9:1),将样品置于恒温水浴锅中搅拌,设置加热温度50℃,进行溶解;
步骤2:将步骤1中的溶液使用喷雾干燥机进行喷雾干燥,得依达拉奉固体分散体,将依达拉奉固体分散体过40目筛网;
步骤3:将步骤2中处理好的依达拉奉固体分散体与除硬脂酸镁外的其他辅料置于三维混合机中,设置混合速度18r/min,混合20分钟;再加入硬脂酸镁,设置混合速度18r/min,混合5分钟;
步骤4:将步骤3中得到的物料然后置于旋转压片机上,压制成单片500mg、硬度80N~160N的椭圆形片芯;
步骤5:将步骤4中得到的素片用胃溶型薄膜包衣预混剂(欧巴代)进行包衣,得到薄膜包衣片。
实施例3-4
依达拉奉缓释片处方组成
制备工艺:
步骤1:将上述处方中的依达拉奉和HPMCAS加入到溶剂中(甲醇:水=9:1),将样品置于恒温水浴锅中搅拌,设置加热温度50℃,进行溶解;
步骤2:将步骤1中的溶液使用喷雾干燥机进行喷雾干燥,得依达拉奉固体分散体,将依达拉奉固体分散体过40目筛网;
步骤3:将步骤2中处理好的依达拉奉固体分散体与除硬脂酸镁外的其他辅料置于三维混合机中,设置混合速度18r/min,混合20分钟;再加入内加的硬脂酸镁,设置混合速度18r/min,混合5分钟;
步骤4:将步骤3得到的混合物置于干法制粒机中,调节设备参数,使之能压制成有一定硬度的大片,再用1.0mm筛网进行整粒;再与外加的硬脂酸镁混合,设置混合速度18r/min,混合5分钟;
步骤5:将步骤4中得到的物料然后置于旋转压片机上,压制成单片600mg、硬度100N~180N的椭圆形片芯;
步骤6:将步骤5中得到的素片用胃溶型薄膜包衣预混剂(欧巴代)进行包衣,得到薄膜包衣片。
实施例5
对以上所制得的依达拉奉缓释片进行释放度测定,所述释放度的测定方法如下:取缓释片剂(n=12),照中国药典2020版二部附录XC第二法,以pH6.8磷酸盐缓冲溶液900ml为溶出介质,转速为50r/min,于1,2,4,6,8,12,16,20,24小时取溶液1.5ml,经10μm的微孔滤膜滤过,采用高效液相(HPLC)方法检测药物累积释放度。溶出结果如下:
实施例6
依达拉奉在各pH水溶液中的溶解度均较低,小于1mg/ml,生物利用度低,因此本实施例中使用了聚合物载体,将依达拉奉制备成固体分散体后,溶解度结果如下:
结果表明,依达拉奉与醋酸羟丙甲纤维素琥珀酸酯制备成固体分散体后,其溶解度提高了6~25倍,因此本发明中将依达拉奉制备成无定形的固体分散体,有利于提高其溶解度,可提高生物利用度;制备成缓释剂型,可使体内血药浓度平稳,降低毒副作用。
Claims (10)
1.一种药物组合物,其中所述药物组合物具有以下特征A)、B)和C):
A)在1小时内溶出不超过35%的药物活性成分;
B)在6小时内溶出30%~65%的药物活性成分;
C)在24小时内溶出不低于75%的药物活性成分;
其中,所述的药物活性成分可以选自依达拉奉、其药学上可接受的盐、水合物和溶剂合物中的一种或多种;
优选地,所述药物组合物优选具有以下特征A)、B)和C):
A)在1小时内溶出不超过30%的药物活性成分;
B)在6小时内溶出30%~60%的药物活性成分;
C)在24小时内溶出不低于75%的药物活性成分;
更优选地,所述药物组合物更优选具有以下特征A)、B)和C):
A)在1小时内溶出不超过25%的药物活性成分;
B)在6小时内溶出35%~60%的药物活性成分;
C)在24小时内溶出不低于80%的药物活性成分。
2.一种药物组合物,其特征在于包括以下组分:药物层和包衣层;所述的药物层包括依达拉奉药物活性成分、聚合物载体、骨架缓释材料和其他辅料;所述的其他辅料包括填充剂、粘合剂、崩解剂和润滑剂中的一种或多种;
所述的依达拉奉药物活性成分包括依达拉奉、依达拉奉药学上可接受的盐、依达拉奉水合物和依达拉奉溶剂合物中的一种或多种;
优选地,所述的依达拉奉药物活性成分的含量为5.0%~65.0%,所述的含量是指以依达拉奉计,依达拉奉药物活性成分的重量占药物组合物总重量的百分比;
优选地,所述的包衣层为薄膜包衣。
3.如权利要求2所述的药物组合物,其特征在于:
所述的聚合物载体选自聚乙二醇、共聚维酮、羟丙甲纤维素、醋酸羟丙甲纤维素琥珀酸酯、羟丙甲纤维素邻苯二甲酸酯、聚醋酸乙烯酯聚维酮混合物、泊洛沙姆和羧甲基乙基纤维素中的一种或多种;
优选地,所述的聚合物载体的含量为10.0%~80.0%,所述的含量是指聚合物载体的重量占药物组合物总重量的百分比;
所述的骨架缓释材料选自羟丙基甲基纤维素、羟丙基纤维素、海藻酸钠、羧甲基纤维素、羧甲基纤维素钠、甲基纤维素、聚丙烯酸树脂、乙基纤维素、卡波姆、硬脂酸、聚氧乙烯、聚醋酸乙烯酯聚维酮混合物、单硬脂酸甘油酯、双硬脂酸甘油酯、山嵛酸甘油酯、十六醇、十八醇、蜂蜡、氢化蓖麻油、巴西棕榈蜡、石蜡、白蜡和微晶蜡中的一种或多种;
优选地,所述的骨架缓释材料的含量为5.0%~50.0%,所述的含量是指骨架缓释材料的重量占药物组合物总重量的百分比。
4.如权利要求2所述的药物组合物,其特征在于:
所述的填充剂选自微晶纤维素、预胶化淀粉、淀粉、乳糖、甘露醇、磷酸氢钙和硅化微晶纤维素中的一种或多种;
所述的粘合剂选自聚维酮、甲基纤维素、羟丙基甲基纤维素、羟乙基纤维素、共聚维酮、羧甲基纤维素钠、羟丙基纤维素和海藻酸钠中的一种或多种;
所述的润滑剂选自硬脂酸钙、硬脂酸镁、硬脂酸锌、硬脂酸、硬脂酸富马酸钠、聚乙二醇、淀粉、滑石粉和石蜡中的一种或多种;
所述的崩解剂选自交联聚维酮、交联羧甲基纤维素钠、交联羧甲基纤维素钙、羧甲基淀粉钠,羟丙纤维素和预胶化淀粉中的一种或多种;
所述的填充剂的含量优选10.0%~60.0%,其中,所述的含量是指填充剂的重量占药物组合物总重量的百分比;
所述的粘合剂的含量优选5.0%~30.0%,其中,所述的含量是指粘合剂的重量占药物组合物总重量的百分比;
所述的润滑剂的含量优选0%~5%,其中,所述的含量是指润滑剂的重量占药物组合物总重量的百分比;
所述的其他辅料的含量为30.0%~80.0%,所述的含量是指其他辅料的重量占药物组合物总重量的百分比。
5.如权利要求2所述的药物组合物,其特征在于:所述的药物组合物选自具有以下重量百分比的任一组分:
组分一:10.0%-30.0%依达拉奉药物活性成分,10.0%-30.0%醋酸羟丙甲纤维素琥珀酸酯,10.0%-30.0%羟丙甲纤维素K4M,5.0%-20.0%羟丙甲纤维素K100Lv,10.0%-30.0%乳糖,5.0%-20.0%微晶纤维素和0.5%-2.0%硬脂酸镁;
组份二:10.0%-30.0%依达拉奉药物活性成分,10.0%-30.0%醋酸羟丙甲纤维素琥珀酸酯,10.0%-30.0%羟丙甲纤维素K100Lv,10.0%-30.0%预胶化淀粉,5.0%-20.0%交联聚维酮,5.0%-20.0%微晶纤维素和0.5%-2.0%硬脂酸镁;
组分三:10.0%-30.0%依达拉奉药物活性成分、40.0%-60.0%醋酸羟丙甲纤维素琥珀酸酯,5.0%-20.0%羟丙甲纤维素K4M,5.0%-20.0%羟丙甲纤维素K100Lv,5.0%-20.0%乳糖,5.0%-20.0%微晶纤维素和0.5%-2.0%硬脂酸镁;
组分四:10.0%-30.0%依达拉奉药物活性成分,40.0%-60.0%醋酸羟丙甲纤维素琥珀酸酯,5.0%-20.0%羟丙甲纤维素K100Lv,5.0%-20.0%预胶化淀粉,5.0%-20.0%交联聚维酮,5.0%-20.0%微晶纤维素和0.5%-2.0%硬脂酸镁;
优选地,所述的药物组合物选自具有以下重量的任一组分:
组分一:20.00%依达拉奉药物活性成分,20.00%醋酸羟丙甲纤维素琥珀酸酯,20.00%羟丙甲纤维素K4M,10.00%羟丙甲纤维素K100Lv,19.00%乳糖,10.00%微晶纤维素和1.00%硬脂酸镁;
组份二:20.00%依达拉奉药物活性成分,20.00%醋酸羟丙甲纤维素琥珀酸酯,19.00%羟丙甲纤维素K100Lv,20.00%预胶化淀粉,10.00%交联聚维酮,10.00%微晶纤维素和1.00%硬脂酸镁;
组分三:16.67%依达拉奉药物活性成分、50.00%醋酸羟丙甲纤维素琥珀酸酯,8.33%羟丙甲纤维素K4M,8.33%羟丙甲纤维素K100Lv,8.33%乳糖,7.34%微晶纤维素和1.00%硬脂酸镁;
组分四:16.67%依达拉奉药物活性成分,50.00%醋酸羟丙甲纤维素琥珀酸酯,8.33%羟丙甲纤维素K100Lv,8.33%预胶化淀粉,7.34%交联聚维酮,8.33%微晶纤维素和1.00%硬脂酸镁。
6.如权利要求2所述的药物组合物,其特征在于:所述的药物组合物为缓释片、缓释胶囊和缓释微丸。
7.如权利要求1-6任一项所述的药物组合物的制备方法,其特征在于:所述制备方法选自湿法制粒法、干法制粒法和直接压片法。
8.如权利要求7所述的药物组合物的制备方法,其特征在于:
所述的湿法制粒包括以下步骤:将依达拉奉药物活性成分和醋酸羟丙甲纤维素琥珀酸酯溶解于甲醇/水溶液中,经喷雾干燥得依达拉奉药物活性成分固体分散体;
将依达拉奉药物活性成分固体分散体与骨架缓释材料及部分其他辅料混合,湿法制粒,干燥,整粒,然后再与润滑剂混合,压片,包衣,即得到依达拉奉药物活性成分缓释片,所述的部分其他辅料包括粘合剂、填充剂和崩解剂中的一种或多种;
所述的干法制粒包括以下步骤:将依达拉奉药物活性成分和醋酸羟丙甲纤维素琥珀酸酯溶解于甲醇/水溶液中,经喷雾干燥得依达拉奉药物活性成分固体分散体;
将依达拉奉药物活性成分固体分散体与骨架缓释材料及部分其他辅料,干法制粒,然后再与外加润滑剂混合,压片,包衣即得到依达拉奉药物活性成分缓释片,所述的部分其他辅料包括粘合剂、填充剂、崩解剂和润滑剂中的一种或多种;
所述的直接压片法包括以下步骤:将依达拉奉药物活性成分和醋酸羟丙甲纤维素琥珀酸酯溶解于甲醇/水溶液中,经喷雾干燥得依达拉奉药物活性成分固体分散体;
将依达拉奉药物活性成分固体分散体与骨架缓释材料和其他辅料混合,压片,包衣得到依达拉奉药物活性成分缓释片。
9.如权利要求1-6任一项所述的药物组合物在制备和/或预防氧化性应激相关疾病的药物中的应用;
优选地,所述的氧化性应激相关疾病选自老年痴呆症、肌萎缩侧索硬化症、帕金森氏病、缺血性心脏病、脑梗/中风、血栓性静脉炎、慢性阻塞性肺疾病、人类免疫系统病/获得性免疫系统综合症和糖尿病。
10.一种治疗和/或预防氧化性应激相关疾病的方法,包括将所述药物组合物给予有需要的患者(例如人);
优选地,所述的氧化性应激相关疾病选自老年痴呆症、肌萎缩侧索硬化症、帕金森氏病、缺血性心脏病、脑梗/中风、血栓性静脉炎、慢性阻塞性肺疾病、人类免疫系统病/获得性免疫系统综合症和糖尿病。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020108713303 | 2020-08-26 | ||
CN202010871330 | 2020-08-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114099500A true CN114099500A (zh) | 2022-03-01 |
CN114099500B CN114099500B (zh) | 2023-09-22 |
Family
ID=80352731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110999891.6A Active CN114099500B (zh) | 2020-08-26 | 2021-08-26 | 依达拉奉缓释药物组合物、制备方法及应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114099500B (zh) |
WO (1) | WO2022042644A1 (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101103964A (zh) * | 2006-07-14 | 2008-01-16 | 海南盛科生命科学研究院 | 一种含有非洛地平的缓释制剂及其制备方法 |
CN104490838A (zh) * | 2014-11-20 | 2015-04-08 | 河北医科大学 | 一种骨架型缓控释片剂及其制备方法和应用 |
CN104814923A (zh) * | 2014-08-21 | 2015-08-05 | 浙江海力生制药有限公司 | 一种盐酸坦洛新缓释制剂及其制备方法和其应用 |
CN105534940A (zh) * | 2016-02-19 | 2016-05-04 | 国药集团致君(深圳)坪山制药有限公司 | 一种双氯芬酸钠缓释片组合物及其制备方法 |
CN105816423A (zh) * | 2016-03-16 | 2016-08-03 | 福建康是美生物科技有限公司 | 依达拉奉剂型 |
WO2019088881A1 (ru) * | 2017-11-03 | 2019-05-09 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Комбинации эдаравона для лечения ишемических повреждений мозга |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105878171A (zh) * | 2014-12-22 | 2016-08-24 | 南京海恒医药科技有限公司 | 一种依达拉奉新制剂及其制备方法 |
CN107773545A (zh) * | 2016-08-29 | 2018-03-09 | 烟台益诺依生物医药科技有限公司 | 依达拉奉与(+)‑2‑莰醇的舌下用药物组合物 |
CN110381923A (zh) * | 2017-01-17 | 2019-10-25 | 萃微Tw001公司 | 包括肠内施用依达拉奉的医学治疗 |
CN110384656A (zh) * | 2018-04-19 | 2019-10-29 | 上海现代药物制剂工程研究中心有限公司 | 依达拉奉鼻腔给药组合物及其鼻给药制剂制备方法 |
CN112089683A (zh) * | 2018-04-27 | 2020-12-18 | 首都医科大学附属北京天坛医院 | 依达拉奉药物组合物 |
-
2021
- 2021-08-26 WO PCT/CN2021/114757 patent/WO2022042644A1/zh active Application Filing
- 2021-08-26 CN CN202110999891.6A patent/CN114099500B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101103964A (zh) * | 2006-07-14 | 2008-01-16 | 海南盛科生命科学研究院 | 一种含有非洛地平的缓释制剂及其制备方法 |
CN104814923A (zh) * | 2014-08-21 | 2015-08-05 | 浙江海力生制药有限公司 | 一种盐酸坦洛新缓释制剂及其制备方法和其应用 |
CN104490838A (zh) * | 2014-11-20 | 2015-04-08 | 河北医科大学 | 一种骨架型缓控释片剂及其制备方法和应用 |
CN105534940A (zh) * | 2016-02-19 | 2016-05-04 | 国药集团致君(深圳)坪山制药有限公司 | 一种双氯芬酸钠缓释片组合物及其制备方法 |
CN105816423A (zh) * | 2016-03-16 | 2016-08-03 | 福建康是美生物科技有限公司 | 依达拉奉剂型 |
WO2019088881A1 (ru) * | 2017-11-03 | 2019-05-09 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Комбинации эдаравона для лечения ишемических повреждений мозга |
Also Published As
Publication number | Publication date |
---|---|
WO2022042644A1 (zh) | 2022-03-03 |
CN114099500B (zh) | 2023-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070275061A1 (en) | Pharmaceutical compositions and formulations of metformin extended release tablets | |
JP4970452B2 (ja) | メトホルミン徐放性錠剤およびその製造方法 | |
KR101999463B1 (ko) | 테소펜신, 베타 차단제 복합 제형 | |
US20210154180A1 (en) | Formulation having improved ph-dependent drug-release characteristics containing esomeprazole or pharmaceutically acceptable salt thereof | |
KR20060120596A (ko) | 로피니롤의 신규 제형 | |
WO2013100630A1 (en) | Fixed dose combination formulation comprising losartan, amlodipine and hydrochlorothiazide | |
EP1487429A2 (en) | Compositions of venlafaxine base | |
EP2603207A2 (en) | Oral controlled release pharmaceutical compositions of blonanserin | |
CN114146062A (zh) | 一种组合物及其制备方法和用途 | |
KR102294190B1 (ko) | 신규한 용출 파라미터를 이용한 모사프리드 함유 서방제제 | |
CN114099500B (zh) | 依达拉奉缓释药物组合物、制备方法及应用 | |
WO2018211336A2 (en) | Solid dosage form containing sorafenib tosylate | |
WO2022042645A1 (zh) | 依达拉奉口服持续释放组合物、制备方法及应用 | |
KR101990951B1 (ko) | 리바스티그민 함유 서방출 의약조성물 | |
TW202227071A (zh) | 為單片基質錠劑形式之控釋型含瑞巴派特醫藥組成物及其製備程序 | |
CN115297848A (zh) | 一种非布司他片 | |
KR101175816B1 (ko) | 경구 서방성 정제 | |
KR20200033751A (ko) | 콜린 알포세레이트를 포함하는 약학 조성물 | |
KR102330953B1 (ko) | 소듐-1-[6-(모르폴린-4-일)피리미딘-4-일]-4-(1h-1,2,3-트리아졸-1-일)-1h-피라졸-5-올레이트를 함유하는 제약 투여 형태 | |
US20100008956A1 (en) | Composition and combinations of carboxylic acid losartan in dosage forms | |
US20220249479A1 (en) | Modified release formulation of a pyrimidinylamino-pyrazole compound, and methods of treatment | |
KR102210422B1 (ko) | 신규한 용출 파라미터를 이용한 이토프라이드 함유 서방제제 | |
KR102189200B1 (ko) | 용출 특성을 조절한 이토프라이드 염산염 함유 경구 투여 서방제제 | |
KR102294186B1 (ko) | 1일 1회 경구투여하는 모사프리드 함유 서방제제 | |
WO2005016315A1 (en) | Pharmaceutical compositions of nateglinide and a high amount of a water-soluble filler |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 201210 Building 1, Lane 647, Songtao Road, Pudong New Area, Shanghai Applicant after: Shanghai Yunshengyan neoplasm Technology Co.,Ltd. Address before: 201203 Building 1, Lane 647, Songtao Road, Zhangjiang High Tech Park, Pudong New Area, Shanghai Applicant before: SHANGHAI BOCIMED PHARMACEUTICAL Co.,Ltd. |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |